tert-butyl (4-chlorobutyl)sulfonyl(methyl)carbamate | 1480815-35-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: tert-butyl (4-chlorobutyl)sulfonyl(methyl)carbamate
• 英文别名: tert-butyl N-(4-chlorobutylsulfonyl)-N-methylcarbamate
• CAS: 1480815-35-7
• 化学式: C₁₀H₂₀ClNO₄S
• 分子量: 285.792
• InChiKey: KQAHAJYYVCBKCT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (4-chlorobutyl)sulfonyl(methyl)carbamate 在 盐酸 、 18-冠醚-6 作用下， 以 二氯甲烷 、 乙酸乙酯 、 乙腈 为溶剂， 反应 20.0h， 生成 4-cyano-N-methylbutane-1-sulfonamide
  参考文献：
  名称：

  Copper-Catalyzed C–N Coupling in the Synthesis of Integrase Inhibitors of Immunodeficiency Viruses

  摘要：

  This contribution describes the total synthesis of a complex macrocyclic integrase inhibitor, a key enzyme involved in the infection process of various immunodeficiency viruses. The key transformation of the synthetic strategy was the selective C-N coupling of a sulfonamide to a heteroaryl bromide in the presence of potentially competing amide and carbamate functionalities. The transformation was accomplished with CuI catalysis using bypiridine as the ligand in the presence of base and enabled a convergent approach to the target molecule.

  DOI：

  10.1021/op400228z
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 N-methyl-4-chlorobutanesulfonamide 在 4-二甲氨基吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 生成 tert-butyl (4-chlorobutyl)sulfonyl(methyl)carbamate
  参考文献：
  名称：

  Copper-Catalyzed C–N Coupling in the Synthesis of Integrase Inhibitors of Immunodeficiency Viruses

  摘要：

  This contribution describes the total synthesis of a complex macrocyclic integrase inhibitor, a key enzyme involved in the infection process of various immunodeficiency viruses. The key transformation of the synthetic strategy was the selective C-N coupling of a sulfonamide to a heteroaryl bromide in the presence of potentially competing amide and carbamate functionalities. The transformation was accomplished with CuI catalysis using bypiridine as the ligand in the presence of base and enabled a convergent approach to the target molecule.

  DOI：

  10.1021/op400228z

文献信息

• MACROCYCLIC INTEGRASE INHIBITORS
  申请人：Thuring Johannes Wilhelmus J

  公开号：US20120172367A1

  公开（公告）日：2012-07-05

  Compound having formula (I), wherein —W is NH—, —N(CH 3 )— or piperazine, —X is a bond, —C(═O)— or S(═O) 2 —, —Y is C 3-7 alkylene, and —Z is NH—C(═O)— or —O—, and pharmaceutically acceptable salts thereof, their pharmaceutical formulations and use as HIV inhibitors.

  具有式(I)的化合物，其中-W是NH-，-N(CH3)-或哌嗪，-X是键，-C(═O)-或S(═O)2-，-Y是C3-7烷基，-Z是NH-C(═O)-或-O-，以及其药学上可接受的盐，其制药配方和用作HIV抑制剂。
• MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS
  申请人：Thuring Johannes Wilhelmus J.

  公开号：US20130296330A1

  公开（公告）日：2013-11-07

  This invention concerns to naphthyridin derivatives of formula (I) for use in the treatment or prevention of feline immunodeficiency virus (FIV). Furthermore the present invention relates to a method of treating or preventing infection of feline immunodeficiency virus in a feline animal wherein said method comprises the administration to said feline animal of a therapeutically effective amount of a naphthyridin derivative.

  本发明涉及式（I）的萘啶衍生物，用于治疗或预防猫免疫缺陷病毒（FIV）。此外，本发明还涉及一种治疗或预防猫动物感染猫免疫缺陷病毒的方法，其中所述方法包括向所述猫动物施用萘啶衍生物的治疗有效量。
• US8497270B2
  申请人：——

  公开号：US8497270B2

  公开（公告）日：2013-07-30